Select Language
CD30
CD30 Overview
| English Name | Tumor necrosis factor receptor superfamily member 8 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 25 | Target Synonym | CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8 |
| Highest Development Stage | Approved | ||
| English Name | Tumor necrosis factor receptor superfamily member 8 |
| Target Synonym | CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 25 |
| Highest Development Stage | Approved |
CD30 Product List
- Product Category
Protein (11)
- Product Status
Launched (11)
- Species
Human (10)Mouse (1)
- Tag
Fc Tag (3)His Tag & Avi Tag (1)Llama IgG Fc Tag (1)His Tag (5)Fc Tag & Avi Tag (1)
- Conjugate
Unconjugated (4)Biotin-labeled (2)FITC Labeled (2)PE Labeled (1)AF488 Labeled (1)AF647 Labeled (1)
Total: 11
- 1
- 2
CD30 Background
Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
CD30 Synonyms
TNFRSF8,CD30,D1S166E,Ki-1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides | Details |
| ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) | Phase 2 Clinical | Unc Lineberger Comprehensive Cancer Center | Hodgkin Disease; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Papulosis; Lymphoproliferative Disorders; Mycosis Fungoides; Neoplasms; Neoplasms, Germ Cell and Embryonal; Sezary Syndrome | Details | |
| Autologous CD30+ CAR T Cells therapy(New York Medical College) | Phase 2 Clinical | New York Medical College, University Of North Carolina At Chapel Hill | Hodgkin Disease | Details | |
| Itezocabtagene autoleucel | TT-11; TT11 | Phase 2 Clinical | Tessa Therapeutics Ltd | Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Primary mediastinal B cell lymphoma | Details |
| BRD-01 | BRD-01 | Phase 2 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms; Hodgkin Disease | Details |
| PRA-052 | PRA-052; MK-8690; PR-600 | Phase 2 Clinical | Prometheus Biosciences Inc | Colitis, Ulcerative | Details |
| HSP-CAR-30 | HSP-CAR-30 | Phase 2 Clinical | Fundació Institut De Recerca De L | Hodgkin Disease; Lymphoma, T-Cell | Details |
| Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) | CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta | Phase 2 Clinical | Pla General Hospital | Hodgkin Disease | Details |
| Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
| CD30.CAR-EBVST cell therapy (Baylor College of Medicine) | TT-11X | Phase 1 Clinical | Baylor College Of Medicine, Tessa Therapeutics Ltd | Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
| EBV-specific-CAR.CD30 | EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine, Methodist Hospital System, Texas Children'S Hospital | Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
| Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Angioimmunoblastic T-cell Lymphoma; Hematologic Neoplasms; Hodgkin Disease; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | Details | |
| B-0069 (Shanghai Pharmaceuticals Holding) | F0002-ADC; B-006(SCP) | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | Details |
| CD30.CAR | H-27721; CD30.CAR | Phase 1 Clinical | Baylor College Of Medicine | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral | Details |
| CD30 CAR-T Cells therapy (Unicar-Therapy Bio-Medicine Technology) | U29 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Lymphoma | Details |
| ATLCAR.CD30.CCR4 | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Lymphoproliferative Disorders; Mycosis Fungoides; Neoplasms; Sezary Syndrome | Details | |
| Chimeric antigen receptor gene modified T cells therapy (Qilu Cell Therapy Engineering&Technology) | Phase 1 Clinical | Shandong Qilu Cell Treapy Engineering&Technology Co Ltd | Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell | Details | |
| Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | Phase 1 Clinical | Shanghai Tongji Hospital | Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell | Details | |
| CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology) | Phase 1 Clinical | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | ||
| SGN-35C | SGN-35C; PF-08046044 | Phase 1 Clinical | Seagen Inc | Hodgkin Disease; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | Details |
| Anti-CD30 CAR T-cell therapy | Phase 1 Clinical | Minghui (Nanjing) Gene Biotechnology Co Ltd | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Hodgkin Disease; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous | Details | |
| Anti-CD30 CAR-T cell therapy (National Cancer Institute) | Hu30-CD28z | Phase 1 Clinical | National Cancer Institute | Enteropathy-Associated T-Cell Lymphoma; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | Details |
| SGN-CD30C | SGN-CD30C | Phase 1 Clinical | Seattle Genetics Inc | Lymphoma | Details |
| Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Hodgkin Disease | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Brentuximab vedotin | cAC10-vcMMAE; SGN-30; cAC10-Val-Cit-MMAE; cAC-10; SGD-1010; SGN-35 | Approved | Seagen Inc | Adcetris, 安适利 | United States | Lymphoma, Large-Cell, Anaplastic; Hodgkin Disease | Seagen Inc | 2011-08-19 | Anemia, Refractory, with Excess of Blasts; Carcinoma; Enteropathy-Associated T-Cell Lymphoma; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Hidradenitis Suppurativa; HIV Infections; Hodgkin Disease; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Papulosis; Mastocytosis, Systemic; Mesothelioma; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Germ Cell and Embryonal; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Kaposi; Scleroderma, Diffuse; Scleroderma, Systemic; Sezary Syndrome; Solid tumours | Details |
Product Reviews
R*** 2021-09-22
3People LikeOur research group work with CAR-T therapy for the treatment of hematological malignancies, and use the Fitc-Labeled Human CD30 protein for detection of CAR30 cells in patients by flow cytometry. Our results are fantastic, because the observe consistency and a reproducible experiments by flow cytometry. The logistic speed is very effective and allows us to work always up to date with our projects.- 1***22020-01-10 0People LikeThere are many CD30 products, with various tags. What I chose was the hFc tag protein. I also purchased CD30L for Fortebio experiment. The result was pretty good.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland